The growing use of copay accumulators — a new weapon against widely used but controversial copay assistance cards that drug makers distribute to consumers — is causing average net prices for medicines to fall, according to a new analysis.
In the first quarter of 2018, net prices after concessions made by drug makers declined 5.6 percent, compared with a 1.7 percent drop in the corresponding quarter a year ago. This occurred even though increases in average wholesale — or list — prices more or less held steady at 6.2 percent versus 6.8 percent in the first quarter of 2017, according to Sector & Sovereign Research, which tracks the pharmaceutical industry.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
